

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Etsuya MATSUTANI et al.
Serial No. :
Filed on :
Title : Agent that Retards Transformation of Hormone-dependent
Cancer to Non-hormone-dependent Cancer
Attn: Box PCT

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97 and 1.98, applicants request consideration of (X) the references listed on the attached Form PTO-1449 and/or () the additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed. ¹

1. This Information Disclosure Statement is submitted:

- a. () within 3 months of the filing date of the above-identified application, or (X) within 3 months of entry into the national phase of the International Application, or () before the mailing date of the first Office Action on the merits, and thus no certification and/or fee is required.
- b. () after the events of above paragraph 1-a and prior to the mailing date of a final Office Action or Notice of Allowance, and thus:
 - () the certification of paragraph 2 below is provided, or
 - () a fee of \$240.00 is enclosed (37 CFR 1.17(p)).
- c. () after the mailing date of a final Office Action or a Notice of Allowance and prior to payment of the issue fee, and thus the certification of paragraph 2 below is provided and a petition and fee of \$130.00 are enclosed (37 CFR 1.17(i)).

2. It is hereby certified that:

- () each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- () no item of information contained in the Information Disclosure Statement

¹ A copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. _____.

JCS Rec'd PCT/PTO 28 MAR 2001

was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Statement.

3. () Consideration of the following additional information (including any co-pending or abandoned U.S. application, prior uses and/or sales, etc.) is requested:
4. For each non-English language reference listed on the attached Form PTO-1449:
- () reference is made to an English language translation submitted herewith, and/or
 - () reference is made to a foreign patent office search report (in the English language) submitted herewith, and/or
 - () reference is made to an English language translation of a foreign patent office search report submitted herewith, and/or
 - () reference is made to the concise explanation contained in the specification of the present application at page(s), and/or
 - () reference is made to the concise explanation attached thereto or contained therein and/or
 - () reference is made to the concise explanation set forth below:
5. () Applicants also offer the following comments for the Examiner's consideration:
6. (X) Also enclosed is a copy of: (X) the International Search Report citing these references, (X) the International Preliminary Examination Report, and () the Written Opinion.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP 609.

Date: March 22, 2001

Respectfully submitted,



Philippe Y. Riesen, Reg. No. 35,657
Mark Chao, Ph.D., Reg. No. 37,293
Attorneys for Applicants
Customer No. 23,115

JC08 d PCT/PTO 28 MAR 2001

Page 1 of 1							
FORM PTO 1449 (modified)				ATTY DOCKET NO.: 2556US0P		SERIAL NO.:	
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO:				APPLICANT: Etsuya MATSUTANI et al.			
				FILING DATE:		GROUP:	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,472,382	Sep. 18, 1984	F. Labrie et al.			
	A2	5,677,171	Oct. 14, 1997	R.M. Hudziak et al.			
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	A3	WO 98/32423	Jul. 30, 1998	WO			
	A4	WO 98/03505	Jan. 29, 1998	WO			
OTHER DOCUMENT(S)							
*EXAMINER INITIAL	REF No.	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.					
	A5	F. Lablie et al. "MEDICAL CASTRATION WITH LHRH AGONISTS AND THE NEED FOR COMBINED TREATMENT WITH AN ANTIANDROGEN IN PROSTATE CANCER", IN: Proc. Annu. Meet. Int. Found. Biochem. Endocrinol, 11th Meeting Edited by McKearns, Menneth W., New York, 1983, pp. 531-549					
	A6	N. Sato et al. "Intermittent Androgen Suppression Delays Progression to Androgen-independent Regulation of Prostate-specific Antigen Gene in the LNCaP Prostate Tumour Model", Journal of Steroid Biochemistry Molecular Biology, Vol. 58 (1996), No. 2, pp. 139-146					
	A7	K. GU et al. "Overexpression of her-2/neu in human prostate cancer and benign hyperplasia", Cancer Letters Vol. 99 (1996), pp. 185-189					
EXAMINER:				DATE CONSIDERED:			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.